Steris (NYSE:STE) updated its FY 2019 earnings guidance on Monday. The company provided earnings per share guidance of $4.74-4.84 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.76. The company issued revenue guidance of $2.751-2.751 billion, compared to the consensus revenue estimate of $2.75 billion.
STE stock traded up $1.27 during midday trading on Monday, reaching $119.86. The stock had a trading volume of 772,423 shares, compared to its average volume of 413,651. The firm has a market capitalization of $10.03 billion, a price-to-earnings ratio of 28.88 and a beta of 1.04. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.63 and a quick ratio of 2.01. Steris has a 52-week low of $83.44 and a 52-week high of $121.67.
STE has been the subject of a number of research analyst reports. Sidoti raised their target price on Steris from $155.00 to $157.00 and gave the stock a buy rating in a research note on Thursday, December 6th. Zacks Investment Research restated a buy rating and issued a $132.00 target price on shares of Steris in a research note on Friday, November 16th. Finally, KeyCorp raised their target price on Steris from $120.00 to $132.00 and gave the stock an overweight rating in a research note on Tuesday, November 13th. Five equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and a consensus price target of $134.20.
In other Steris news, VP John Adam Zangerle sold 3,000 shares of the stock in a transaction dated Friday, January 25th. The stock was sold at an average price of $115.00, for a total transaction of $345,000.00. Following the sale, the vice president now directly owns 33,796 shares of the company’s stock, valued at approximately $3,886,540. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.38% of the stock is currently owned by company insiders.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Featured Article: Insider Trading
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.